Learn how testosterone health, combined with chiropractic rehabilitation, can improve physical strength and hormonal balance.

Educational Abstract: Integrative, Evidence-Based Strategies to Evaluate and Restore Optimal Testosterone in Men

In this educational post, I, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, walk men and clinicians through a clear, step-by-step approach to evaluating and restoring optimal testosterone using modern, evidence-based, and integrative methods. I explain central versus peripheral hypogonadism; why men with “normal” but low testosterone can remain symptomatic and at risk; and which core labs (LH, FSH, total and free testosterone, estradiol/SHBG) are essential to determine the true breakdown in the hypothalamic–pituitary–gonadal (HPG) axis. I review risks and benefits of delivery systems (transdermal vs injectable), clarify the aromatase–estradiol feedback loop, and outline adjunctive strategies (e.g., clomiphene, hCG, kisspeptin analog frameworks, CJC no DAC and ipamorelin protocols), while grounding the discussion in physiology, safety, and individualization.

I also explain how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas integrates chiropractic medicine, internal medicine, functional medicine, personal injury rehabilitation, and precision lifestyle programs. Our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933), brings more than 40 years of internal medicine expertise and provides medical oversight and co-management alongside me, Dr. Alex Jimenez, DC. Together, we deliver a comprehensive, patient-centered pathway to address hypogonadism and its drivers—metabolic, inflammatory, biomechanical, and neuroendocrine—using high-quality research methods and outcome measures. This post synthesizes leading research findings, clinical decision trees, and practical care plans to help patients make informed decisions and clinicians define integrative protocols.

IntegrativeMen’ss Health: Why Low-Normal Testosterone Is Not “Fine”

I meet many 40- to 60-year-old men who feel exhausted, unfocused, less resilient, and unable to recover from training or injuries, yet they are told: “Your lab is normal.” When I see a total testosterone around 300–400 ng/dL in a symptomatic man, I do not stop at the reference range. I ask: Is the HPG axis intact? Is signaling from hypothalamus to pituitary to testes coherent? Is testosterone getting into cells as free hormone? Is estradiol suppressing LH through negative feedback? Is sex hormone–binding globulin (SHBG) trapping testosterone? Is inflammation sabotaging Leydig cell function? Are comorbidities like sleep apnea, visceral adiposity, insulin resistance, thyroid dysfunction, or medications dragging the system down?

This is not a cosmetic issue. A robust body of evidence connects suboptimal testosterone with loss of lean mass, lower bone density, unfavorable body composition, insulin resistance, diminished aerobic capacity, depressive symptoms, and—in several cohorts—higher all-cause mortality when levels fall very low. My responsibility is to determine the exact failure point and personalize interventions accordingly, not merely “replace” hormone by default.

Key points:

• A “normal” lab range can be misleading in symptomatic men.
• Systems thinking is essential: endocrine, metabolic, inflammatory, neurologic, and biomechanical factors interact.
• The first goal is correct diagnosis: central (signal) vs peripheral (factory) hypogonadism, plus binding and conversion dynamics.

The HPG Axis: The Control System That Determines Male Testosterone

The male HPG axis is a tightly regulated loop:

• Hypothalamus secretes gonadotropin-releasing hormone (GnRH) in pulses.
• The pituitary responds with luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
• LH stimulates Leydig cells in the testes to synthesize testosterone from cholesterol via steroidogenic enzymes (e.g., CYP11A1, 17?-HSD).
• FSH supports Sertoli cells and spermatogenesis.
• Testosterone and estradiol provide negative feedback at the hypothalamus and pituitary to regulate GnRH/LH/FSH output.
• Sex hormone–binding globulin (SHBG) binds circulating testosterone. Only the unbound (free) fraction is bioactive and enters cells to engage androgen receptors.

Breakdown can occur centrally (hypothalamus/pituitary) or peripherally (testes), and binding/clearance dynamics can create “functional” hypogonadism even with acceptable total testosterone.

Distinguishing Central from Peripheral Hypogonadism: The Four Core Labs

When men present with fatigue, low libido, decreased morning erections, reduced exercise capacity, loss of strength, or mood and cognitive changes, I start with four essential tests to pinpoint the problem:

• LH (luteinizing hormone)
• FSH (follicle-stimulating hormone)
• Total testosterone (morning, fasting, 7–10 a.m. when feasible)
• Free testosterone (via equilibrium dialysis or accurate direct methods) with SHBG and albumin to calculate free testosterone when needed

Complement with:

• Estradiol (sensitive assay, LC–MS/MS preferred)
• Prolactin (screen for hyperprolactinemia)
• Thyroid panel (TSH, free T4, free T3)
• CBC, CMP, fasting insulin and glucose, HbA1c or OGTT, lipid profile
• hs-CRP, ferritin, vitamin D, B12, folate, magnesium, zinc
• Morning cortisol or diurnal salivary cortisol where indicated
• Consider LH pulsatility issues, sleep apnea screening, and medication review (opioids, SSRIs, finasteride, glucocorticoids)

Interpretation logic:

• Low LH/FSH with low testosterone suggests central hypogonadism (hypothalamus/pituitary under-signaling).
• High LH/FSH with low testosterone suggests primary/peripheral hypogonadism (testicular failure or resistance).
• Low free testosterone with “normal” total testosterone often reflects high SHBG or altered albumin, resulting in functional hypogonadism.
• Elevated estradiol can suppress LH through negative feedback, lowering endogenous testosterone production.

In practical thresholds:

• LH less than about 3 IU/L with low testosterone supports central hypogonadism.
• LH above about 8 IU/L with low testosterone supports peripheral hypogonadism.
• Elevated FSH in particular may indicate impaired spermatogenesis or more entrenched testicular dysfunction.

Why these matter: Interventions differ profoundly. Central hypogonadism might respond to restoring hypothalamic signaling (address sleep apnea, energy availability, stress physiology), selective estrogen receptor modulators (SERMs) like clomiphene to boost endogenous LH/FSH, or addressing hyperprolactinemia. Peripheral hypogonadism may call for hCG to stimulate Leydig cells, address toxin exposure or varicocele, or, when indicated, exogenous testosterone with careful monitoring.

Free Testosterone, SHBG, and Bioavailability: The Real-World Androgen Signal

Men live and function on free testosterone. High SHBG can trap testosterone, lowering free levels even when total looks fine. SHBG rises with aging, hyperthyroidism, liver disease, low insulin/low calorie states, and some medications. SHBG falls with insulin resistance and obesity. Therefore:

• Always pair total testosterone with SHBG and free testosterone.
• Track symptoms alongside free testosterone trends over time.
• Recognize that correcting SHBG drivers (thyroid status, nutrition, liver health) can restore free testosterone without immediate hormone therapy.

Estradiol, Aromatase, and Negative Feedback: When E2 Silences LH

Aromatase converts testosterone to estradiol, especially in adipose tissue. Elevated estradiol can suppress LH and dampen endogenous testosterone production. Men with central hypogonadism patterns may be experiencing aromatase-driven feedback suppression. Clinical clues:

• Increased adiposity, gynecomastia, water retention, mood swings.
• Labs show high-normal or elevated estradiol with low/normal LH and low testosterone.

Addressing the source—visceral fat, alcohol intake, hepatic congestion, inflammatory cytokines—often normalizes estradiol and restores LH pulsatility. I don’t use aromatase inhibitors first-line unless carefully indicated; we prefer to remove upstream drivers and protect bone, joints, lipids, and cognition.

Delivery Systems: Why Transdermal Testosterone Often Underperforms

I evaluate delivery routes through pharmacokinetics, pharmacodynamics, and patient safety. Transdermal preparations can cause variable absorption, higher local skin aromatase exposure, and, in some men, disproportionate estradiol elevation. Some studies have found higher estradiol levels among men using transdermal routes compared to injectables. Clinically, I see:

• Fluctuating serum testosterone with peaks and troughs tied to application timing.
• Unpredictable estradiol elevation with symptoms like water retention, gynecomastia, and mood changes.
• Risk of secondary exposure to partners or children.

Injectable regimens (e.g., testosterone cypionate or enanthate) allow steady-state optimization via split dosing (e.g., twice weekly), often with more predictable estradiol dynamics. However, no route is universally “best.” We individualize based on labs, symptoms, comorbidities, fertility goals, adherence, and adverse-event profiles under medical oversight.

Mortality and Healthspan: Testosterone as a Systems Integrator

Lower testosterone is associated with adverse cardiometabolic, musculoskeletal, cognitive, and immunologic outcomes. Cohorts tracking men over many years have shown that very low testosterone correlates with higher all-cause mortality, while mid-to-higher physiological ranges align with better survival and health parameters. Mechanisms include:

• Muscle and bone: Testosterone supports protein synthesis, satellite cell activation, and osteoblast function, reducing sarcopenia and fracture risk.
• Metabolism: Improves insulin sensitivity, mitochondrial biogenesis, and lipid handling, reducing ectopic fat deposition.
• Cardiovascular: Modulates vascular tone, endothelial nitric oxide pathways, and inflammatory signaling.
• Brain: Influences dopaminergic tone, mood, motivation, working memory, and executive function.
• Immunity: Modulates innate and adaptive responses, tending to lower chronic low-grade inflammation.

The goal is not supraphysiology; it is restoring physiology.

An Integrative Algorithm: From Evaluation to Targeted Intervention

Our El Paso workflow integrates chiropractic care, internal medicine, functional medicine, and rehabilitation into a single, coordinated plan.

• History and symptom mapping
• Fatigue patterns, libido, sleep (including snoring, witnessed apneas), mood/cognition, recovery, training tolerance.
• Medications and exposures (opioids, SSRIs, finasteride, glucocorticoids, alcohol, endocrine disruptors).
• Reproductive plans (fertility), prior testosterone or anabolic use, injury and pain patterns.
• Physical examination
• Body composition, waist circumference, blood pressure, signs of metabolic syndrome.
• Testicular size/consistency, gynecomastia, varicocele suspicion.
• Musculoskeletal assessment: posture, spinal mechanics, pelvic alignment, thoracic mobility, breathing mechanics.
• Core labs and extensions
• LH, FSH, total and free testosterone, SHBG, estradiol.
• Thyroid, prolactin, CBC/CMP, iron studies, B12/folate, vitamin D, fasting insulin/glucose/A1c, lipids, hs-CRP.
• Sleep study when indicated; diurnal cortisol; heavy metals or EDCs in select cases.
• Categorize
• Central hypogonadism, peripheral hypogonadism, mixed/secondary to systemic issues, functional hypogonadism with high SHBG, aromatase-driven suppression, or transient suppression (overtraining, energy deficit).
• Address root contributors
• Sleep apnea management, weight reduction strategies, anti-inflammatory nutrition, resistance training periodization, stress physiology recalibration, alcohol moderation, medication review.
• Select therapy
• Fertility-preserving stimulation (clomiphene, enclomiphene, hCG) for central cases.
• hCG or combined strategies for partial peripheral cases; consider urology input for structural testicular issues.
• Testosterone therapy when appropriate, with shared decision-making, informed consent, and monitoring.
• Adjunctive peptide-based strategies in select cases (clinical research contexts and within regulatory guidance).
• Integrative chiropractic and rehab to restore biomechanics, respiratory mechanics, and autonomic balance to support neuroendocrine function.
• Monitor and adapt
• Symptom scales, strength metrics, body composition, serial labs, blood pressure, hematocrit, PSA where indicated, sleep metrics, and mood/cognition.

Central Hypogonadism: Mechanisms, Workup, and Treatment Rationale

What goes wrong centrally?

• Hypothalamic suppression from stress hypercortisolemia, chronic sleep restriction, energy deficiency/RED-S, illness, or elevated estradiol.
• Pituitary disorders: hyperprolactinemia, adenomas, infiltrative disease, or medication effects.
• Obstructive sleep apnea: intermittent hypoxia blunts nocturnal GnRH/LH pulsatility.
• Obesity-related inflammation: cytokines (IL-6, TNF-?) alter hypothalamic signaling.

Workup priorities:

• Prolactin: Elevated prolactin suppresses GnRH and LH/FSH. If elevated, evaluate for pituitary lesions or medications (e.g., antipsychotics).
• Thyroid: Hypothyroidism can mimic or exacerbate hypogonadal symptoms.
• Sleep study: Treating OSA can restore morning testosterone and improve LH pulsatility.
• Iron overload (ferritin, transferrin saturation) can deposit in the pituitary/hypothalamus.
• Consider MRI if severe unexplained central hypogonadism, visual changes, headaches, galactorrhea, or very high prolactin.

Treatment logic:

• Remove suppressors: Treat OSA with CPAP or oral appliance; discontinue or replace offending medications when possible; correct thyroid and iron disorders; reduce alcohol; decrease visceral fat; optimize sleep.
• Restore signaling: SERMs such as clomiphene or enclomiphene can increase endogenous LH/FSH, raising intratesticular testosterone, preserving fertility. Dosing is individualized and monitored for visual symptoms, mood changes, lipids, and estradiol.
• Consider hCG: Mimics LH at the testis, supports testosterone production and fertility; can be used alone or with SERMs.
• Investigational/adjunctive routes: Kisspeptin-based approaches and GHRH/GHRP stacks (CJC no DAC plus ipamorelin) are discussed in research and some clinical practices to improve upstream pulsatility and body composition; these require careful oversight due to regulatory status and safety concerns.

Chiropractic and rehab integration:

• Thoracic mobility and rib cage mechanics influence respiratory efficiency and the risk of sleep-disordered breathing; targeted mobilization, breathing drills, and cervical/thoracic alignment can support OSA therapies.
• Autonomic balance: Pain and dysautonomia drive HPA-axis activation; spinal manipulation and myofascial work can improve vagal tone, sleep quality, and perceived stress—indirectly supporting GnRH pulsatility.
• Exercise programming: Progressive resistance programming restores lean mass and increases androgen receptor density, potentiating endogenous testosterone effects.

Peripheral Hypogonadism: Testicular Failure and Leydig Cell Dysfunction

Mechanisms:

• Testicular damage from mumps orchitis, trauma, torsion, chemotherapy, radiation, varicocele, toxins (phthalates, pesticides), or autoimmune processes.
• Age-related Leydig cell loss and reduced steroidogenic enzyme activity.
• Genetic conditions (Klinefelter syndrome) or Y-chromosome microdeletions.

Evaluation:

• High LH and/or FSH with low testosterone.
• Semen analysis if fertility is a goal.
• Scrotal ultrasound for varicocele or structural pathology.
• Endocrine disruptor exposure assessment, occupational history.

Treatment logic:

• When Leydig cells retain partial function: hCG can stimulate testosterone production and support spermatogenesis (with FSH or SERMs in select fertility cases).
• When testicular capacity is limited: Testosterone replacement therapy (TRT) with informed consent, vigilant monitoring, and concurrent fertility planning (e.g., baseline cryopreservation or periodic hCG).
• Address toxins and oxidative stress; support mitochondria and steroidogenesis with evidence-informed nutrition (adequate cholesterol, vitamin D, zinc, magnesium) and anti-inflammatory lifestyle interventions.

Chiropractic role:

• Pain and pelvic floor dysfunction can lower sexual function and increase stress hormones. Lumbopelvic alignment, hip mobility, and pelvic floor coordination reduce nociception, improve confidence and sexual activity—factors associated with better androgen profiles.
• Whole-body mechanics enable higher-quality resistance training and energy availability, reinforcing anabolic signaling.

Signs of Hormonal Imbalances In Men *THIS IS WHY*- Video

Functional Hypogonadism: SHBG, Estradiol, and “Normal” Totals With Low Bioavailability

Functional hypogonadism emerges when:

• SHBG is elevated, reducing free testosterone.
• Estradiol suppresses LH.
• Chronic inflammation and nutrient deficits impair steroidogenesis despite “acceptable” total testosterone.

Treatment logic:

• Normalize thyroid function and liver health to modulate SHBG.
• Reduce visceral fat and alcohol to decrease aromatase.
• Replete vitamin D, magnesium, zinc; ensure adequate protein and cholesterol for steroidogenesis.
• Optimize sleep duration and quality to restore nocturnal testosterone rise.
• Progressive resistance training plus adequate caloric/energy availability.

We re-measure free testosterone after correcting these drivers; many men improve without exogenous hormones.

Estradiol Management: Balance, Not Elimination

Estradiol in men supports bone, joints, libido, and vascular health. Excess estradiol can suppress LH and drive symptoms, but overly aggressive aromatase inhibition can harm bone, mood, and lipids. Strategy:

• Prioritize lifestyle drivers of aromatase.
• Use pharmacologic aromatase inhibitors only when necessary, at the lowest effective dose, with monitoring of bone, lipids, and symptoms.
• Consider timing injections and dosing to minimize peaks that overshoot aromatase capacity.

Delivery Systems Compared: Pharmacokinetics, Symptom Stability, and Safety

Injectables (testosterone cypionate/enanthate):

• Advantages: Predictable levels with split dosing; lower contact transfer risk; often steadier estradiol control.
• Considerations: Hematocrit elevation risk; require needles and adherence; dosing needs personalization.

Transdermals (gels/creams):

• Advantages: No needles; daily microdosing; potentially lower erythrocytosis risk.
• Considerations: Absorption variability; potential for higher estradiol in some men; transfer risk to contacts.

Pellets:

• Advantages: Long-acting, adherence-friendly.
• Considerations: Surgical implantation; less flexible titration; potential for supra-physiologic peaks or long lows.

Oral testosterone undecanoate (select regions):

• Advantages: Oral route; lymphatic absorption model.
• Considerations: Dosing frequency; GI variability; lipid and liver considerations vary by formulation.

I counsel men using shared decision-making. We trial, monitor, and adjust based on physiology and lived experience.

Clomiphene, Enclomiphene, hCG, Kisspeptin Frameworks, CJC no DAC, and Ipamorelin: When and Why

Clomiphene citrate (SERM):

• Mechanism: Blocks estrogen receptors at the hypothalamus/pituitary, disinhibiting GnRH and boosting LH/FSH.
• Use cases: Central hypogonadism with fertility goals; younger men with suppressible aromatase feedback; post-anabolic suppression.
• Monitoring: Vision changes, mood, estradiol dynamics, lipids.

Enclomiphene:

• The trans-isomer is thought to target hypothalamic-pituitary effects more specifically, with fewer estrogenic peripheral effects reported in some data.
• Clinical consideration: Similar monitoring; may be preferred for men prioritizing fertility and endogenous testosterone.

hCG:

• Mechanism: LH receptor agonist at Leydig cells, increasing intratesticular testosterone; can support spermatogenesis with FSH in select cases.
• Use cases: Central or partial peripheral hypogonadism; fertility preservation during TRT; post-cycle re-stimulation.
• Monitoring: Estradiol, hematocrit, symptoms, testicular response.

Kisspeptin-based approaches:

• Concept: Kisspeptin stimulates GnRH neurons, restoring physiologic pulsatility upstream. Emerging research highlights potential utility in functional hypothalamic hypogonadism.
• Clinical note: Requires regulatory awareness and specialist oversight; promising in theory for central suppression due to stress/energy deficits.

CJC no DAC and ipamorelin (GHRH analog plus GHRP):

• Rationale: Improve body composition, sleep architecture, and recovery, indirectly supporting anabolic milieu and possibly HPG axis tone via improved metabolic health and reduced inflammation.
• Clinical note: Not a substitute for HPG-specific therapy; adjunctive, with careful sourcing, legality, and safety monitoring.

I employ these tools within comprehensive plans, not in isolation.

Chiropractic, Neurobiomechanics, and Endocrine Cross-Talk

My chiropractic lens focuses on the nervous system’s control of structure and function. Pain, malalignment, restricted thoracic and pelvic mechanics, and altered breathing patterns feed sympathetic dominance and HPA axis activation. Over time, this can suppress GnRH/LH pulsatility. Our integrated approach:

• Precise spinal adjustments to normalize segmental motion and reduce nociception.
• Thoracic mobility work to improve respiratory mechanics; better oxygenation and sleep quality support endocrine balance.
• Diaphragmatic breathing drills and rib mechanics to reduce upper-chest over-breathing that perpetuates sympathetic overdrive.
• Pelvic alignment and lumbopelvic stabilization to allow productive resistance training—critical for testosterone signaling.
• Myofascial interventions to downshift pain, improve sleep, and enhance exercise tolerance.

These methods support hormonal interventions by lowering stress load and enabling the lifestyle changes that drive durable testosterone restoration.

Clinical observations:

• Men who regain hip and thoracic mobility improve lifting mechanics, reclaim training intensity, and report increased morning erections within weeks—often before hormonal labs fully shift.
• Addressing cervicothoracic dysfunction reduces tension headaches and improves sleep continuity, correlating with better morning testosterone.

(For more clinical perspectives, see: Dr. Alex Jimenez’s insights at https://chiropracticscientist.com/ and professional updates at https://www.linkedin.com/in/dralexjimenez/.)

Internal Medicine Oversight: Dr. Maria Guadalupe Cardenas’ Role in Our Clinic

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, our multidisciplinary framework is anchored by medical direction from Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933). With over four decades of internal medicine practice, Dr. Cardenas provides:

• Medical evaluation for endocrine, cardiometabolic, and sleep comorbidities.
• Safety oversight for pharmacologic therapies (SERMs, hCG, testosterone), including contraindication screening and risk mitigation.
• Coordination with urology, endocrinology, sleep medicine, and cardiology when needed.
• Co-develop protocols with me to integrate chiropractic, functional medicine, and rehabilitation into cohesive care plans.

Why this matters:

• Hormone therapy is never isolated from cardiometabolic risk.
• Men benefit from one integrated team aligning lab interpretation, medication management, biomechanics, and lifestyle therapeutics.
• This model reflects best practices in integrative and injury care clinics, where an MD provides medical direction alongside a chiropractor to deliver comprehensive, safe, and effective outcomes.

Functional Medicine Foundations: Nutritional and Lifestyle Strategies That Move the Needle

Nutrition:

• Protein: 1.6–2.2 g/kg/day to support muscle protein synthesis and androgen receptor signaling.
• Micronutrients: Ensure adequate vitamin D, zinc, magnesium, selenium, and B vitamins. Zinc and magnesium participate in steroidogenic enzymes and androgen receptor function.
• Fats: Include mono- and saturated fats for steroidogenesis while prioritizing overall cardiometabolic health.
• Phytonutrients: Polyphenols (e.g., from berries, olive oil) reduce inflammation and may modulate aromatase indirectly.
• Alcohol moderation: Reduces aromatase activity and hepatic burden.

Body composition:

• Prioritize visceral fat reduction with resistance training and energy balance; improved insulin sensitivity correlates with better testosterone.

Sleep:

• 5–9 hours; treat sleep apnea; consistent circadian routines; sleep is a primary driver of nocturnal testosterone rise.

Stress and recovery:

• Autonomic retraining, breathwork, and realistic training periodization prevent overreaching and central suppression.

Environmental health:

• Minimize exposure to endocrine disruptors (plastics, pesticides) that impair Leydig function and increase aromatase.

Personal Injury and Testosterone: The Overlooked Connection

Trauma and chronic pain alter endocrine function through inflammatory cytokines, sleep disruption, and stress physiology. In personal injury contexts:

• Acute and chronic pain elevate cortisol and lower LH pulsatility.
• Immobility reduces muscle mass and insulin sensitivity.
• Opioids suppress GnRH and testosterone.

Our approach:

• Early mobilization and pain control using non-opioid strategies.
• Chiropractic adjustments and rehab to restore movement patterns and autonomic balance.
• Sleep support and anti-inflammatory nutrition to reduce cytokine load.
• HPG axis reassessment as pain resolves—often testosterone rebounds with function.

Monitoring, Safety, and Long-Term Outcomes

When we use TRT or stimulation therapies, we monitor:

• Symptom scores and quality-of-life metrics.
• Testosterone (total/free), estradiol, SHBG, LH/FSH as appropriate.
• Hematocrit/hemoglobin, PSA (age-appropriate), lipids, liver enzymes, blood pressure.
• Fertility parameters when relevant.
• Sleep quality and apnea treatment adherence.

We adjust dosing to the lowest effective levels that restore function without adverse effects. We continuously reassess the need for therapy as lifestyle and health improve.

Case Archetypes: Translating Physiology Into Practice

Case 1: Central suppression with high estradiol

• 47-year-old with snoring, visceral adiposity; low LH/FSH, low T, elevated estradiol.
• Plan: CPAP for OSA, weight loss, resistance training, reduce alcohol, consider clomiphene to restore LH/FSH; avoid aromatase inhibitor initially.
• Outcome: Free T and symptoms improve; estradiol normalizes with fat loss.

Case 2: High SHBG functional hypogonadism

• 52-year-old with normal total T but low free T; elevated SHBG; hyperthyroid edge and low caloric intake.
• Plan: Normalize thyroid dosing, increase energy intake and protein, resistance training, evaluate for liver health.
• Outcome: Free T rises without exogenous hormones; symptoms resolve.

Case 3: Primary testicular failure

• 44-year-old with high LH/FSH, low T; prior mumps orchitis.
• Plan: Discuss fertility; trial hCG; if inadequate, transition to TRT with periodic hCG for testicular support.
• Outcome: Stable symptoms and function with monitored TRT.

How Integrative Chiropractic Care Complements Endocrine Therapy

• Pain reduction lowers sympathetic drive and HPA activation, allowing HPG recovery.
• Improved biomechanics enables higher-quality training, which naturally elevates testosterone and insulin sensitivity.
• Breathing mechanics improvements support sleep quality; better sleep drives nocturnal testosterone rhythms.
• Patient engagement increases—when men feel better moving, they sustain the habits that keep hormones optimized.

Our Multidisciplinary Process at Injury Medical Clinic PA

• Intake with me (Dr. Alex Jimenez, DC, APRN, FNP-BC) and our team to map symptoms and mechanics.
• Medical evaluation with Dr. Maria Guadalupe Cardenas, MD, for labs, imaging, and pharmacologic considerations.
• Coordinated plan: chiropractic adjustments, rehab, nutrition, sleep, stress interventions, and endocrine therapy as indicated.
• Follow-up cadence: 6–8 weeks initially for lab and symptom review; adjust protocols; re-test at 3–4 months; transition to maintenance.

This integrated loop turns evidence into outcomes.

Practical Takeaways for Patients

• If you are 45 with symptoms and a total testosterone of 300–400 ng/dL, you deserve a deeper evaluation.
• Ask for LH, FSH, free testosterone, SHBG, and sensitive estradiol.
• Treat sleep apnea, reduce visceral fat, and prioritize resistance training.
• Consider fertility goals before starting exogenous testosterone.
• Seek a team that integrates medical oversight with chiropractic, functional medicine, and rehabilitation.

Practical Takeaways for Clinicians

• Always pair total testosterone with free testosterone and SHBG.
• Distinguish central vs peripheral hypogonadism before selecting therapy.
• Leverage lifestyle and biomechanical interventions to amplify endocrine gains.
• Choose delivery systems by pharmacokinetics, patient preference, and safety.
• Monitor hematocrit, PSA (as age/risks dictate), estradiol, lipids, and symptoms.

Closing Perspective

My commitment is to restore physiology, not chase numbers. With a clear diagnostic algorithm, collaborative medical oversight from Dr. Maria Guadalupe Cardenas, MD, and a robust integrative toolkit—chiropractic care, rehabilitation, functional medicine, and selective pharmacology—we help men reclaim energy, strength, cognition, and vitality safely and sustainably. The path forward is personal, data-driven, and comprehensive.

If you are ready for a structured, integrative plan, our team at Injury Medical Clinic PA in El Paso is prepared to help.

References

• Journal of Clinical Endocrinology & Metabolism: Association of Testosterone Levels With Mortality and Health Outcomes
• Endocrine Society Clinical Practice Guidelines on Testosterone Therapy in Men With Hypogonadism
• European Urology Association and American Urological Association: Male Hypogonadism and Testosterone Therapy Guidance
• Sleep Medicine Reviews: Obstructive Sleep Apnea and Testosterone
• Lancet Diabetes & Endocrinology: Functional Hypogonadism in Men
• Andrology: Clomiphene and Enclomiphene in Male Hypogonadism
• Reproductive Biology and Endocrinology: hCG Mechanisms in Leydig Cell Function
• Nature Reviews Endocrinology: Kisspeptin Physiology and Clinical Applications
• Sports Medicine: Resistance Training and Endocrine Adaptations
• Circulation: Testosterone, Endothelium, and Cardiovascular Health

Note: Where possible, sensitive assays (LC–MS/MS) and standardized protocols should be used for hormone measurement. Clinicians should consult the full-text guidelines and primary studies for specific recommendations, dosing, and monitoring standards.

SEO tags: testosterone optimization, male hypogonadism, central hypogonadism, peripheral hypogonadism, free testosterone, SHBG, estradiol, aromatase, clomiphene, enclomiphene, hCG, kisspeptin, CJC ipamorelin, transdermal vs injectable testosterone, TRT safety, men’s health, sleep apnea and testosterone, functional medicine, chiropractic care, integrative medicine, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC